Durable and dramatic response to checkpoint inhibition combined with COX-2 inhibitor celecoxib in a patient with p16+ metastatic sinonasal undifferentiated carcinoma: A case study
Document Type
Article
Abstract
BACKGROUND: Sinonasal undifferentiated carcinoma (SNUC) is an exceedingly rare head and neck malignancy. No consensus exists on treatment for metastatic disease. CASE: A 56-year-old female was diagnosed with SNUC after endorsing sinus congestion, diplopia, and right orbital pain. Initially treated with surgery and radiation, she later developed significant metastatic disease. She demonstrated progression of her hepatic metastases under pembrolizumab therapy. However, the addition of ipilimumab and a COX-2 inhibitor resulted in significant improvement in her lesions as well as an ongoing durable response. Her regimen was complicated by immune-related adverse events successfully treated with steroids. CONCLUSION: Dual checkpoint inhibition deserves consideration when treating metastatic SNUC, especially after single agent therapy has failed. The positive effect of this treatment may be augmented by IDO1 inhibition.
Publication Date
10-22-2023
Publication Title
Cancer reports (Hoboken, N.J.)
E-ISSN
2573-8348
First Page
e1915
PubMed ID
37867289
Digital Object Identifier (DOI)
10.1002/cnr2.1915
Recommended Citation
Trinh, Jonathan Q.; Acosta, Cassaundra; Easwar, Arti; Galamaga, Robert; and Tan, Alan, "Durable and dramatic response to checkpoint inhibition combined with COX-2 inhibitor celecoxib in a patient with p16+ metastatic sinonasal undifferentiated carcinoma: A case study" (2023). ENT and Skull Base Surgery. 20.
https://scholar.barrowneuro.org/ent-and-skull-base-surgery/20